Advanced Pancreatic Cancer
Advanced metastatic pancreatic adenocarcinoma (mPAC) is increasing in frequency, but is still associated with a poor prognosis, with a five-year survival rate less than 5% and median overall survival of 4-6 months. Nearly 85% of patients diagnosed with mPAC have an unresectable disease and limited treatment options.
Revive Research Institute is conducting a clinical trial investigating an investigational second-line treatment for patients with advanced pancreatic cancer. The purpose of the study is to establish the maximum tolerated dose of the investigational drug in combination with a chemotherapy regimen and evaluate its safety and effectiveness.
Participation Criteria:
- Adults 18 years of age or older, male or female
- Confirmed pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent
- Have at least one measurable tumor lesion
- Additional Criteria may apply
Our research team will monitor participants throughout the study and address questions or concerns related to the clinical trial.
The investigational treatment is provided at no cost for the duration of the clinical trial, and insurance is not required. All patient records and information will be kept secure and confidential. Eligible participants may also receive reimbursement for their time and travel.